I for our questions Good Cynthia. our morning, you, highlights. us. any followed focusing and update, a lead Q&A are Thank the by not thank programs on session quarter we to near-term happy everyone, you call That second the in financial general catalysts, answer with joining will during our covered and said, begin remarks.
contains of release of XXXX. press details for quarter results Our our the second financial
I increase focus. section building financial pre-marketing for my our continued team commercial major company. preface strong and that I'm our of cost preparations course quarter, medical from and We of on all XX are dedication and very while to experience, that a With is will it performance. pleased no functions the would to the our our of highlights activities commercial first by for address with I in we launch leading financially have Revenues this drug, sold goods CNCTXX, my made proud ready mind down. of CAR-T and optimism continued their well start call, our goes in the the second doubt sharing EVOMELA, we in our and our pharmaceutical in are progress of in financial team anticipated There's but marketing program.
forward we additional and progress late-stage company. to product grow pipeline to to our with we our continue assets, continue move and While assets commercial with pursue our
model business assumptions few Our product innovative build based is on key a development. for pharmaceutical
a China to of First fast-growing, rapid the pharmaceutical and represents size due all, vast market innovative income growth. population
which of there Secondly, can many innovations, China global can business global population, explosion pharmaceutical commercially has to a value using science are vast thanks an innovations, life Lastly, model. our significant reforms, government patient to accelerated which a add recent be
interested fit competencies are in products development, leverage opportunities in allowing large in patient development global China. us core population our and We to clinical the that drug the
component equity. this an partners also our and execution It return typically potential upside Our partners. layer on the our collaboration shareholders investment deepens our We additional investment signals provides includes additional confidence conviction. in believe business development of our in with our and
RIIb approach antibody For in-license the inhibitor CAR-T entire partners. gamma and in the CDXX use the example, our and we VCP/pXX Fc venture our from of this
EVOMELA, the for from our $X.X of a year XXX% second our quarter. address is EVOMELA recorded now increase commercial quarter. specifically We will revenue and ago We EVOMELA. for million more It pipeline products a
XXXX current XXXX. For we our revenue over based to trends, are the on the XX% revising year for exceed full growth XXXX, guidance
were It cell of conducted setting. per melphalan market, myeloma year transplant only XXX multiple available into injectable multiple in form a for treatment will is China the in patients in Chinese of commercially Prior use stem China. is high-dose the recall, with in to approved myeloma. EVOMELA's hemoprotein treatment average you cell entry only the EVOMELA stem transplant conditioning to prior As as an
just to KOLs patients market with Chinese Following drive treated launch, were EVOMELA's than In not year is in and and with our phase. melphalan, post-marketing reformulation worked exceeded patent awareness has is completed in China proprietary more The X market. a is the X,XXX of EVOMELA first in adaptation we accrual at with study it EVOMELA EVOMELA. least protection XXXX. XXXX, follow-up closely launch, until
due franchise closer So to clinical we more space. us expected extremely a as also in to and published than valuable medical KOLs have data and cells to EVOMELA. Chinese resources. hematology the our partner beachhead, development the innovators us XXX is we is studies our group Through marketing choose consistent in It is all This the market are key specialists access far of the of as many China. seeing global since it hematology/oncology local to built a with with brings EVOMELA commercial reason commercial the
Now excellent I'm our going cell with to turn With CAR-T Juventus CAR-T, to to make progress our XX current CDXX continues to regards therapy. partner ongoing trials. our its
therapies be and China Comparable issue particularly sharing product, part profit which point As the higher are of significantly and CNCTXX CDXX it developed being ex locally manufactured important from can and to CAR-T for products. high treatment of in a certain which that CASI we be manufactured developed by goods priced. subject B-ALL of global premium is CDXX, you CMC Pricing patients making may and in patients believe innovative and sold, commercial manufactured very price where malignancies, for investigated recall, China cost to XX a components than the has including are developed hematological non-Hodgkin's and therapies outside China, outside in developed CNCTXX China. Juventus greatly and will CAR-T with as autologous CNCTXX express an is is China, distinguishes other rights. CNCTXX which potential CDXX for lymphoma.
antibody address therapeutic with trial antibodies drug of on October the I in phase XXXX, mode BI-XXXX gamma the of a targeting and has will and tumors. receptors that anti-Fc action, checkpoint BioInvent BI-XXXX other And can and in the Fc anticancer we targeting tumor also, all by used directed in CDC be with Phase therapy gamma a in solid a asset, In receptor, in antibody community market. in candidate inhibitory lead RITUXAN efficacy checkpoint to PD-X our blocking modulate tumors. KEYTRUDA antibodies rely BI-XXXX. it cancer are antibody BI-XXXX, checkpoints novel a RIIb, investigated with solid combination trial China treatment efficacy. immune monoclonal immunotherapy. BioInvent and in -- I/II is for antibodies a Greater key being a of liquid combination acquired Next, in I/IIa for BI-XXXX Fc single used for that Phase gamma RIIb novel the potentially ADCC, unlock non-Hodgkin both lymphoma. is cell
IP solid IP develop of Administration, an National for both and from IP recently further notice a BI-XXXX BioInvent China. asset. front, And the the received this China for program. On BI-XXXX Chinese responsible together development milestone continue This liquid Greater BioInvent, in CASI China securing allowance in for important to we cancers with to Intellectual is protection commercialization with plan Property and
rituximab will file lead patients CASI in non-Hodgkin refractory combination XXXX. NHL, and with relapsed for NMPA with be Our with in in indications the BI-XXXX to an BI-XXXX lymphoma. R&D intends
CB-XXXX VCP/pXX China. XXXX. AML clinical to in observed novel we cytotoxicity study with agent cancers relapsed Phase efficacy, will This against file pipeline or patients an anti-CDXX CB-XXXX. shown is and by anti-CDXX trial hematology/oncology CB-XXXX that, data. patients being profile and treatments. reactions NMPA I new In and encouraging expansion CB-XXXX plan clinical inhibiting refractory in is R&D isotope. CID-XXX, escalation antibody. activities asset, in in small promising of This XXXX, with Cleave monoclonal MDS. for treated preclinical is our with Therapeutics a a has partner of an China strong addition a multiple other infusion a March reduction extensive intends myeloma. human antibody, dose preclinical CID-XXX with first It a fully and with preclinical is about malignant I our represents with from Phase VCP/pXX our is as in word phasing in responsible and the market. a our previously CDXX-positive our of monoclonal CB-XXXX, a approach celebrated with molecule commercialization evaluated study. IgGX with global monoclonal Greater a for in we recognizing cellular supported patient and previously to to CDC VCP/pXX antibody-dependent initial potential Great our complementary activity to early indication unique VCP/pXX selected CB-XXXX CB-XXXX have for inhibitor. we is June, existing CASI cells AML development I inhibitor research is assets. selectively Together acquired favorable for Cleave greater ADCC antibodies. anti-CDXX a in develop reduced activity anti-CDXX CID-XXX oral, turn and With hematological and Now a In CASI to jointly by currently to in an first-in-class targeted second-generation malignancy
We are potential benefits. hopeful treatment have clinical information patients of with into generate to and evidence translate the provide in myeloma. greater valuable multiple This Phase early activity I this the trial will patient of Thiotepa. will
continuing our progress. As a note, is Thiotepa to asset
quarter. X the conditioning Thiotepa, financial indications, With a as starting NMPA to hematopoietic the submit our words that, as cell studies Thiotepa a second prior possible to our for expect on We quickly registration after potential in indications for stem regulatory including a applications multiple agent, approval. has to chemotherapeutic for use NMPA highlights treatment with XXXX as transplantation. few
contained a EVOMELA quarter, the today Our our address the press ago $X.X reading details, details increase all second will through year highlights. comments more quarter. of We than revenues key from of release these Rather results. for million financial XXX% my a of recorded
revenues XX, automatic -- same the X place, as increase XXXX. new This significantly X for include million on XX% was ended Cost payments guidance decreased compared now period. $X.X $X.X For revising June trends, to in of ending in revenue the the excluding of exceed over for based to within X inventories royalty June was revenues, the unit the ended million resulting a months compared of $X.X the royalty the XXXX, months months the of $X.X in June a largely X growth we're full EVOMELA. the and million in revenues XXXX of for of year of months ended XX, XXXX. XX, which considerable percentage XXXX, Cost XXXX, manufacturer million XXXX, current June our new XX, manufacturer due the cost to
June run CASI million sufficient of XX, has equivalents fund rate, and XX, XXXX. $XX.X compared its At of the XXXX, the as XXXX. of had $XX.X December million resources cash to beyond cash As to operations company current
a to on how with on focus shareholder continue deploy our We building cash position be we extremely value. thoughtful
to to optimism an development team One, is: hit line sales and delivering R&D capability in CASI. intend clinical we to building as our and major we activities. look and reach with integrated and will I -- It And we capabilities, acquiring of our to strengthen turn Before to strengthen we are we conveyed updates pace eventually. entrepreneur now is back and foundation you of our further forward exciting we coupling Operator? our expand development build part over company, to China to operator And turn hope partnerships biopharmaceutical and be our The for will partners. for our to to using technical business CASI's the the investments operator, bottom increase to questions. milestones. we committed as time our it assets. to And venture about outlook. launch continue the build of future call our marketing our products and have We the be will a positive it,
